Epigenomics AG, a pioneering biotechnology company headquartered in Germany, focuses on the development of innovative molecular diagnostics for cancer detection. Founded in 1998, the company has established itself as a leader in the field of epigenetics, particularly with its flagship product, Epi proColon, which is designed for non-invasive colorectal cancer screening. With a strong presence in Europe and North America, Epigenomics AG is committed to advancing personalised medicine through its unique biomarker-based technologies. The company has achieved significant milestones, including regulatory approvals and partnerships that enhance its market position. By leveraging cutting-edge research and development, Epigenomics AG continues to drive advancements in cancer diagnostics, making a meaningful impact on patient care and outcomes.
How does Epigenomics AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Epigenomics AG's score of 15 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Epigenomics AG, headquartered in Germany, currently does not have available data on carbon emissions, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions or any established reduction targets. In the absence of concrete emissions data, it is important to note that the company may still be engaged in climate commitments or initiatives typical within the biotechnology sector. However, without specific information on their climate pledges or reduction strategies, it is challenging to provide a detailed overview of their environmental impact or sustainability efforts. As the industry increasingly focuses on reducing carbon footprints and enhancing sustainability, it is likely that Epigenomics AG will align with these trends in the future.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Epigenomics AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.